evaluated the effects of AMV 564, a novel bivalent CD33/CD3 T-cell engager and showed immunodepletion of MDSC and anti-tumor activity using primary samples of myelodysplastic syndrome (MDS) patients and a disseminated leukemia mouse model (70). The gene discussed is CD33; the disease is neoplasm.